Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.7
4.6
Journals
Antibiotics
Special Issues
Innovative Treatments for Hospital-Acquired Multidrug-Resistant Bacterial Infections
share announcement

Innovative Treatments for Hospital-Acquired Multidrug-Resistant Bacterial Infections

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotic Therapy in Infectious Diseases".

Deadline for manuscript submissions: closed (31 December 2025) | Viewed by 2928

Special Issue Editors

Prof. Dr. Lucas de Paula Ramos

E-Mail Website
Guest Editor
1. School of Dentistry, Federal University of Alfenas—UNIFAL, R. Gabriel Monteiro da Silva, 700—Centro, Alfenas 37130-001, MG, Brazil
2. Laboratory “Health Systemic Process” (P2S), UR4129, Faculty of Medicine Laennec, University Claude Bernard Lyon 1, University of Lyon, 7 Rue Guillaume Paradin, 69008 Lyon, France
Interests: antimicrobial agents; clinical microbiology; cell biology; biomaterials; immunology
Prof. Dr. Cristina Pacheco-Soares

E-Mail Website
Guest Editor
Laboratory of Cell Compartment Dynamics, Institute of Research and Development, University of Vale do Paraíba, São José dos Campos, Brazil
Interests: cell biology; antimicrobial agents; photodynamic therapy
Special Issues, Collections and Topics in MDPI journals
Dr. Hugo Vigerelli

E-Mail
Guest Editor
Laboratório de Bioquímica, Instituto Butantan, São Paulo, Brazil
Interests: peptides; antimicrobial agents; biochemistry
Prof. Dr. Florence Carrouel

E-Mail
Guest Editor
Laboratory Health Systemic Process—P2S, UR4129, Faculty of Medicine Laennec, University Claude Bernard Lyon 1, University of Lyon, Lyon, France
Interests: microbiology and host interaction; oral healthy and systemic diseases; periodontal diseases

Special Issue Information

Dear Colleagues,

The escalating prevalence of hospital-acquired multidrug-resistant bacterial infections (MDRIs) represents a dual crisis in modern medicine, demanding urgent innovation in antimicrobial therapies. Clinically, these infections lead to severe complications, prolonged hospitalizations, and increased mortality, particularly among immunocompromised patients, post-surgical cases, and ICU admissions. Traditional antibiotics often fail against resistant strains, leaving limited treatment options and forcing reliance on last-resort drugs with significant toxicity. Economically, MDRIs impose staggering costs due to extended ICU stays, complex infection control measures, and the need for expensive salvage therapies burdening healthcare systems already under strain. Without novel interventions, such as phage therapy, next-generation antibiotics, and precision antimicrobial strategies, the financial and human toll will intensify. Investing into advanced therapeutics is not just a scientific priority but a public health necessity, leading to reduced morbidity, curbed resistance spread, and alleviated unsustainable economic burden on global healthcare infrastructure.

We invite readers of this prestigious journal to contribute their recent discoveries regarding the fight against multidrug-resistant microorganisms.

We look forward to receiving your contributions.

Acknowledgments: We would like to thank Dr. Diego Garcia, a young scientist, who will serve as the specialist advisor for this Special Issue, for his valuable contributions. His daily clinical experience provides crucial insights into this alarming public health issue, and we greatly appreciate his participation.

Prof. Dr. Lucas de Paula Ramos
Prof. Dr. Cristina Pacheco-Soares
Dr. Hugo Vigerelli
Prof. Dr. Florence Carrouel
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobial agents
  • gram-negative aerobic rods and cocci
  • vancomycin resistance
  • cross-infection
  • infection control

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

10 pages, 293 KB  
Case Report
Cefiderocol for Treatment of Ventriculitis (4MRGN A. baumannii)—Results of Therapeutic Drug Monitoring in Blood and Cerebrospinal Fluid
by Melita Hadzifejzovic, David Guevara Lara and Samir G. Sakka
Antibiotics 2026, 15(2), 139; https://doi.org/10.3390/antibiotics15020139 - 31 Jan 2026
Viewed by 695
Abstract
Background: Cefiderocol, a siderophore cephalosporin, is approved for the treatment of infections caused by multi-drug-resistant Gram-negative bacteria (MRGN). At present, few data are available on the pharmacokinetics of this substance in critically ill patients, particularly for the treatment of central nervous system [...] Read more.
Background: Cefiderocol, a siderophore cephalosporin, is approved for the treatment of infections caused by multi-drug-resistant Gram-negative bacteria (MRGN). At present, few data are available on the pharmacokinetics of this substance in critically ill patients, particularly for the treatment of central nervous system infections. Patients and Methods: Here, we reported on a 22-year-old male patient after severe open head trauma. Initial screening revealed colonization with 4MRGN A. baumannii (OXA-23) (perianal) and 4MRGN K. pneumoniae (KPC) (tracheal). Unfortunately, he developed ventriculitis (4MRGN A. baumannii). According to microbiological testing, the patient with normal renal function received 3 × 2 g/d i.v. cefiderocol as a prolonged infusion (3 h) and colistin 3 × 3 Mio. IU/d i.v. for 2 weeks. In addition to serum trough levels, drug monitoring was performed in the cerebrospinal fluid (CSF) via external ventricular drainage (24 h aliquots). Results: Serum and CSF specimens analyzed by liquid chromatography–mass spectroscopy (LC-MS) in the presence of severe meningeal inflammation yielded average CSF concentrations of cefiderocol from 5.48 to 8.40 (median 6.98) μg/mL and a concentration ratio CCSF mean/Cserum trough from 0.38 to 0.76 (median 0.48). The cefiderocol levels in the CSF were sufficient for eradication of A. baumannii. A subsequent CSF infection with K. pneumoniae (found initially in screening and resistant to cefiderocol) after completed treatment with cefiderocol was successfully treated with gentamicin (intrathecally) and ceftazidime/avibactam (i.v.). However, the patient died due to a Candida tropicalis infection detected in the CSF on day 71. Conclusions: Our results indicate that standard dosages of cefiderocol are sufficient for treatment of CNS infections in the presence of a severe disruption of the blood–CSF barrier. Full article
(This article belongs to the Special Issue Innovative Treatments for Hospital-Acquired Multidrug-Resistant Bacterial Infections)
►▼ Show Figures

Figure 1

7 pages, 239 KB  
Case Report
Imipenem/Relebactam Plus Aztreonam: First Reported Use in MDR Klebsiella pneumoniae Sternal Infection Complicated by Bacteremia
by Luca Pipitò, Raffaella Rubino, Rita Immordino, Eleonora Bono, Teresa Fasciana, Celestino Bonura, Giovanni Maurizio Giammanco, Vincenzo Argano and Antonio Cascio
Antibiotics 2025, 14(10), 1007; https://doi.org/10.3390/antibiotics14101007 - 10 Oct 2025
Cited by 2 | Viewed by 1881
Abstract
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a significant therapeutic challenge, particularly when multiple resistance mechanisms, such as metallo-β-lactamases (MBLs) and Klebsiella pneumoniae carbapenemase (KPC), coexist. Case description: We describe a case of a 51-year-old male with a post-sternotomy surgical site infection and concurrent [...] Read more.
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a significant therapeutic challenge, particularly when multiple resistance mechanisms, such as metallo-β-lactamases (MBLs) and Klebsiella pneumoniae carbapenemase (KPC), coexist. Case description: We describe a case of a 51-year-old male with a post-sternotomy surgical site infection and concurrent bacteremia caused by a CRKP. Sternal swab and mediastinal liquid culture results highlighted CRKP harboring blaNDM and blaKPC genes, while the blood isolate showed blaCTX and blaKPC, indicating phenotypic resistance to ceftazidime-avibactam. All the strains exhibited phenotypic susceptibility to meropenem-vaborbactam (MEV), despite having a high minimum inhibitory concentration. Following clinical failure of MEV-based therapy, combination treatment with aztreonam (ATM) and imipenem/cilastatin/relebactam (IMI/REL), plus gentamicin, was initiated. Therapy was well tolerated and resulted in microbiological eradication and full clinical recovery. The patient completed 49 days of ATM and IMI/REL without relapse over a 3-month follow-up period. This is, to the best of our knowledge, the first reported case of IMI/REL being used in combination with ATM. Full article
(This article belongs to the Special Issue Innovative Treatments for Hospital-Acquired Multidrug-Resistant Bacterial Infections)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop